




RealRate

PHARMACEUTICAL 2017

Astria Therapeutics Inc. Rank 166 of 292





RealRate

PHARMACEUTICAL 2017

Astria Therapeutics Inc.
Rank 166 of 292



The relative strengths and weaknesses of Astria Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Astria Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 95% points. The greatest weakness of Astria Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 58% points.

The company's Economic Capital Ratio, given in the ranking table, is 54%, being 52% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	39,528
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,325
Liabilities, Non-Current	266
Other Assets	113
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	2,532
Other Net Income	-502
Other Revenues	0
Property and Equipment	568
Research and Development	25,450
Selling, General and Administrative Expense	10,108

Output Variable	Value in 1000 USD
Assets	40,209
Liabilities	11,123
Expenses	35,558
Revenues	0
Stockholders Equity	29,086
Net Income	-36,060
Comprehensive Net Income	-36,060
Economic Capital Ratio	54%